Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Coincident inhibition of EGFR signalling predominantly in basal keratinocytes leads to cutaneous adverse events. Only adverse reactions of the skin secondary to EGFRI treatment are addressed in this section. Patients usually experience mild to moderate symptoms that tend to improve during treatment, yet in some cases severe adverse events and progression of skin toxicities are reported. The typical changes seen during EGFRI treatment are:
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
